CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
抗肿瘤 CAR-NK 的制备：谁是最理想的供应者？
英文原题：Manufacturing CAR-NK against tumors: Who is the ideal supplier?
查看英文原题
Manufacturing CAR-NK against tumors: Who is the ideal supplier?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体-自然杀伤（CAR-NK）细胞已成为继 CAR-T 细胞之后肿瘤免疫治疗领域的又一重要角色。CAR-NK 细胞的独特特征使其有可能弥补 CAR-T 治疗的不足，例如制造过程的复杂性、临床不良事件以及实体瘤挑战。迄今为止，来自不同同种异体来源的 CAR-NK 产品在临床前研究中已展现出显著的抗肿瘤效果，并逐渐应用于临床实践。然而，每种来源各有优缺点。选择合适的来源可能有助于最大化 CAR-NK 细胞的疗效并提高临床转化的可行性。因此，本综述讨论了不同来源 CAR-NK 细胞的发展与挑战，为未来的探索提供参考。
展开英文摘要原文
Chimeric antigen receptor-natural killer (CAR-NK) cells have emerged as another prominent player in the realm of tumor immunotherapy following CAR-T cells. The unique features of CAR-NK cells make it possible to compensate for deficiencies in CAR-T therapy, such as the complexity of the manufacturing process, clinical adverse events, and solid tumor challenges. To date, CAR-NK products from different allogeneic sources have exhibited remarkable anti-tumor effects on preclinical studies and have gradually been applied in clinical practice.
However, each source has advantages and disadvantages. Selecting a suitable source may help maximize CAR-NK cell efficacy and increase the feasibility of clinical transformation.
Therefore, this review discusses the development and challenges of CAR-NK cells from different sources to provide a reference for future exploration.
论文信息
- 作者
- Guo F、Zhang Y、Cui J
- 单位
- The First Hospital of Jilin University, Cancer Center, Changchun 133021, China.China
- 期刊
- Chinese journal of cancer research = Chung-kuo yen cheng yen chiu2024 Feb 29
- 原文标识
- PubMed 38455373 · DOI 10.21147/j.issn.1000-9604.2024.01.01
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →